Medicine · Longevity · First Human Trial
The FDA has just cleared the first human trial to reverse biological aging at the cellular level. Here is how it works - and what it means that we got here.
On January 28, 2026, the US Food and Drug Administration cleared a gene therapy for its first-ever human trial - not to treat a tumor, not to correct a genetic defect, but to do something that has never been done before in clinical medicine: reverse the biological age of living cells. The question that has haunted biology since Shinya Yamanaka won the Nobel Prize is about to get its first answer in a human being.
The therapy is called ER-100, and it is the first clinical product built on a technology called partial epigenetic reprogramming. It was developed by Life Biosciences, a company co-founded by Harvard geneticist David Sinclair, whose laboratory has spent the better part of two decades building the scientific case that aging is not an inevitable biological process but something closer to accumulated damage - and that the damage can be repaired.
The FDA's clearance of the Investigational New Drug (IND) application for ER-100 marks the formal opening of the first Phase 1 human trial (clinical trial identifier NCT07290244). Patients with two specific conditions - open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION) - will receive injections of the therapy directly into the eye. The trial is assessing safety and tolerability first, as all Phase 1 trials must, but it will also collect data on visual function, methylation patterns, and the therapy's downstream effects on cellular age markers.
The eye was chosen for reasons that are both practical and scientifically compelling. The retina is one of the few tissues where cells damaged by age and disease cannot regenerate on their own. Retinal ganglion cells - the neurons that carry visual signals from the eye to the brain - are exquisitely vulnerable to elevated pressure (as in glaucoma) and to sudden loss of blood supply (as in NAION). Once they die or lose function, vision degrades in ways that current medicine cannot reverse. The eye also offers something most organs cannot: direct, non-invasive measurement of therapeutic effect. Vision tests are precise, objective, and repeatable. If ER-100 is working, the researchers will know.
Every cell in your body carries the same DNA - the same 3-billion-letter instruction manual. What makes a liver cell different from a neuron, different from a retinal ganglion cell, is not the underlying sequence. It is the epigenome: a dense layer of chemical annotations applied to the DNA and its packaging proteins, controlling which genes are switched on and which remain silent.
Think of it as the difference between a musical score and a performance. The score (the DNA) does not change. The performance - which notes are emphasized, which passages are quiet - is governed by the conductor and the players responding to each other in real time. The epigenome is that dynamic performance layer. It is shaped by development, by environment, by the signals the cell receives from its neighbors. And it drifts as we age.
Sinclair's "information theory of aging" proposes that this drift is the central driver of aging itself. The cell does not forget how to function because its DNA degrades - the sequence stays largely intact. It forgets because the epigenetic annotations accumulate noise over time, the way a recording degrades with each copy. The instructions become garbled. The wrong genes switch on. The right ones go quiet. The cell loses its identity, becomes confused about what it is supposed to do - and eventually fails.
In 2006, Japanese scientist Shinya Yamanaka made a discovery that many biologists initially refused to believe. By introducing just four proteins - OCT4, SOX2, KLF4, and MYC, now known as the Yamanaka factors - into ordinary skin cells, he could drive them backwards through developmental time, erasing their specialized identity and converting them into a state of near-limitless potential: induced pluripotent stem cells (iPSCs).
The implication was extraordinary. The cell's epigenome - its entire accumulated history of annotations - could be wiped clean and rewritten. Age, as encoded in the epigenome, appeared to be reversible. Yamanaka shared the Nobel Prize in Physiology or Medicine in 2012 for the discovery.
The problem was obvious: a cell that completely forgets its identity can grow without restraint. Full reprogramming in living tissue produces teratomas - tumors that contain hair, teeth, fragments of tissue from multiple organ types, the grotesque result of cells reverting to a primordial, uncommanded state. You cannot cure aging by turning patients into a source of uncontrolled growth.
Partial reprogramming - using only some of the factors, for a limited time, in a controlled way - was the insight that transformed the field. If you dial back the reprogramming before the cell loses its identity, something remarkable happens: the epigenetic noise clears. The annotations that had drifted with age are partially reset. But the cell remembers what it is. The retinal ganglion cell remains a retinal ganglion cell - just a younger one.
Life Biosciences' ER-100 uses three of the four factors: OCT4, SOX2, and KLF4. MYC - the one with the most aggressive cell-proliferation effects - is deliberately omitted. The three-factor combination, known as OSK, has been shown in multiple preclinical studies to induce epigenetic rejuvenation without triggering dedifferentiation. The therapy delivers the OSK genes in an adeno-associated virus (AAV) vector - a modified, non-replicating virus that carries the genetic payload into the target cell - administered as a direct injection into the vitreous cavity of the eye.
The AAV does not permanently alter the cell's DNA sequence. It delivers the OSK instructions transiently, allowing a brief window of reprogramming before the factors are cleared. In that window, the methylation patterns that encode biological age are partially reset. The experiment is asking: can we give an aging, damaged cell a new chance at being what it was designed to be?
The journey to the first human trial runs through a series of increasingly compelling animal experiments - experiments that have shifted the field's consensus from skepticism to cautious excitement over less than a decade.
The most striking result came from aged mice. In studies from Sinclair's laboratory and its spinout Rejuvenate Bio, systemic delivery of the OSK gene system extended the median remaining lifespan of aged male mice by 109%. These were old mice - the equivalent of elderly humans - whose remaining life expectancy was dramatically extended not by slowing new damage but by appearing to reverse existing biological age. The mice showed improvements not just in survival but in multiple health parameters: tissue function, gene expression patterns, and the methylation clocks that serve as molecular proxies for cellular age.
In the eye specifically, OSK therapy in mouse models of glaucoma and age-related vision loss restored visual function. The retinal ganglion cells that had lost their ability to respond to light regained activity. The epigenetic clock in those cells - measured by DNA methylation patterns across hundreds of sites - was wound backwards. The cells appeared, by molecular measurement, younger.
Life Biosciences then extended this work to non-human primates - rhesus macaques - a critical step because the primate visual system is far more similar to the human one than the mouse retina. The results, presented at international conferences on aging in 2025, showed safety and the restoration of visual function markers without evidence of dedifferentiation or tumor formation. These were the data that gave the FDA enough confidence to clear the IND.
One of the tools that has made this science possible is an algorithm developed by Sinclair's laboratory at Harvard called "dash AI." It works by imaging individual cells under a microscope and analyzing the visual patterns of the cell's interior - patterns that correlate with biological age in ways the human eye cannot detect but a trained neural network can.
The system can determine, within nanoseconds, whether a cell came from a 20-year-old or a 93-year-old. It can assess, without any genetic sequencing, whether a cell that has been treated with an age-reversal compound is genuinely younger by biological measure. In a field where the most common objection to longevity claims is "but how do you actually know the cell is younger?" this kind of AI-enabled measurement tool is the difference between a compelling story and evidence.
The methylation clocks used in the ER-100 trial work on a related principle: they measure biological age by the pattern of methyl groups attached to specific sites across the genome, a pattern that changes predictably with age in ways that are consistent enough across individuals to function as a molecular clock. If ER-100 is resetting cellular age, the clock will show it.
The current trial is narrow by design. It tests ER-100 in a small number of patients with two specific conditions. It is assessing safety above all else. In regulatory terms, it is the first step of a long process - not the end of the story but the beginning of one that may take years to tell. And yet the implications of even a partial success reach far beyond ophthalmology.
The eye is, in this context, a proof of principle. If OSK partial reprogramming can safely rejuvenate retinal ganglion cells in humans - if the methylation clocks rewind, if visual function improves, if there are no tumors and no catastrophic immune responses - then the same approach becomes applicable to every tissue that age damages. The logic of the technology does not care what kind of cell it is working in. It is resetting a universal feature of the aging process.
Life Biosciences already has preclinical programs targeting liver disease. Other groups are investigating OSK-based therapies for the musculoskeletal system, the kidney, the brain. Sinclair's laboratory has published work on systemic delivery in mice - not the targeted, local injection used in ER-100 but a body-wide reset. That work is years behind the eye program in terms of safety data, but it exists, and it points toward what the field is ultimately trying to build: not just a treatment for one disease but a broad tool for slowing or reversing the biological processes that produce most diseases simultaneously.
The question is no longer whether cells can be made younger. The question is whether we can do it safely enough, specifically enough, and at sufficient scale that it changes what aging means for the human body.
Lisa PedrosaThe risks are real and not fully understood. Even partial reprogramming at the wrong dose, or in the wrong tissue, or in a patient with undetected pre-cancerous cells, could produce serious adverse events. The immune response to AAV vectors remains a concern. Long-term effects on cellular identity - whether the "reset" creates subtle instabilities that only manifest years later - will only become clear through extended follow-up.
There is also the deeper philosophical challenge. If aging is indeed programmable - if the information encoded in a young epigenome can be recovered, the way data can be recovered from a corrupted file if the original is intact somewhere - then we are not merely extending the trailing edge of a human life. We are changing the relationship between time and biology. The oldest patients in the trial are being asked, in effect, whether their cells remember being young. The answer will shape medicine for a very long time.
The trial results are expected by the end of 2026 or early 2027. For the first time, those results will come not from a laboratory animal but from a person who went to a clinic, received an injection, and then waited to find out whether the clock could be turned back.
© 2026 Lisa Pedrosa · lisapedrosa.com
All articles cited to primary institutional or peer-reviewed sources
Buy me a coffee